Journal Mobile Options
Table of Contents
Vol. 35, No. 3, 2010
Issue release date: October 2010
Neuroepidemiology 2010;35:178–184

Progressive Multifocal Leukoencephalopathy Deaths in the USA, 1979–2005

Yorita Christensen K.L. · Holman R.C. · Hammett T.A. · Belay E.D. · Schonberger L.B.
Division of Viral and Rickettsial Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Ga., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Progressive multifocal leukoencephalopathy (PML) is a neurological disease most often seen among immunosuppressed patients. The incidence of PML increased with an increasing incidence of HIV/AIDS. We describe recent trends and the epidemiology of PML-associated death in the era of highly active antiretroviral therapy (HAART). Methods: National multiple-cause-of-death data for the USA were used to identify records with PML listed as a cause of death during 1979–2005. Age-adjusted PML-associated death rates were calculated overall and by sex, race, region and HIV status. Results: The PML-associated death rates peaked in the mid-1990s and decreased from 2.76 deaths per 1 million persons in 1992–1995 to 0.66 in 2002–2005. This decrease was mainly due to a decreasing death rate among PML decedents with HIV diagnosis, males and those aged 20–49 years at death. A decline in death rate was also seen among PML decedents without HIV diagnosis, although this trend was not significant. Decedents in the latter time period were more often female, and older. The proportion of HIV-associated deaths from PML decreased between 1992–1995 (1.4%) and 2002–2005 (1.0%). Conclusion: PML mortality has decreased significantly since 1996 when HAART became the standard of care in the USA. This decline likely reflects increased survival among HIV-positive persons who receive HAART.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Aström KE, Mancall EL, Richardson EP Jr: Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 1958;81:93–111.
  2. Walker DL, Padgett BL: The epidemiology of human polyomaviruses. Prog Clin Biol Res 1983;105:99–106.
  3. Padgett BL, Walker DL: Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467–470.
  4. Brooks BR, Walker DL: Progressive multifocal leukoencephalopathy. Neurol Clin 1984;2:299–313.
  5. Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC: Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991;41:1733–1736.
  6. Holman RC, Török TJ, Belay ED, Janssen RS, Schonberger LB: Progressive multifocal leukoencephalopathy in the United States, 1979–1994: increased mortality associated with HIV infection. Neuroepidemiology 1998;17:303–309.
  7. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 2001;285:1308–1315.
  8. Centers for Disease Control and Prevention: 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR Recomm Rep 1997;46:1–46.
  9. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Sáag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276:146–154.
  10. Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Mertenskötter T, Eggers C, Stellbrink HJ: Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998;12:1149–1154.
  11. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE: HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999;52:623–625.
  12. Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D: Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 1999;13:1881–1887.
  13. Miralles P, Berenguer J, Garcia de Viedma D, Padilla B, Cosin J, López-Bernaldo de Quirós JC, Muñoz L, Moreno S, Bouza E: Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998;12:2467–2472.
  14. Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Lüke W, Lazzarin A, Weber T, Cinque P: Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000;30:95–99.
  15. Wyen C, Hoffmann C, Schmeisser N, Wöhrmann A, Qurishi N, Rockstroh J, Esser S, Rieke A, Ross B, Lorenzen T, Schmitz K, Stenzel W, Salzberger B, Fätkenheuer G: Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004;37:1263–1268.
  16. Wyen C, Lehmann C, Fätkenheuer G, Hoffmann C: AIDS-related progressive multifocal leukoencephalopathy in the era of HAART: report of two cases and review of the literature. AIDS Patient Care STDS 2005;19:486–494.
  17. Gasnault J, Taoufik Y, Goujard C, Kousignian P, Abbed K, Boué F, Dussaix E, Delfraissy JF: Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 1999;5:421–429.
  18. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, Domingo P, Márquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Lacruz Rodrigo J, Mallolas J, de Miguel V, GESIDA 11/99 Study Group: Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003;36:1047–1052.
  19. US Department of Health and Human Services: Vital statistics mortality data, multiple cause detail, 1979–2005: public-use data tape contents and documentation package. Hyattsville, Centers for Disease Control and Prevention, National Center for Health Statistics, 2009.
  20. World Health Organization: Manual of the international statistical classification of diseases, injuries, and causes of death, based on recommendations of the ninth revision conference, 1975, ed 9. Geneva, World Health Organization, 1977.
  21. World Health Organization: International Statistical Classification of Diseases and Related Health Problems (ICD-10), ed 10. Geneva, World Health Organization, 1992.
  22. Documentation for the public-use multiple-cause-of-death file on comparability between ICD-9 and ICD-10: a double-coded file based on the 1996 data year multiple-cause-of-death file. Hyattsville, National Center for Health Statistics,–10/ICD9_ICD10_comparability_file_documentation.pdf (accessed December 4, 2009).
  23. Anderson RN, Miniño AM, Hoyert DL, Rosenberg HM: Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. National Vital Statistics Reports. Hyattsville, National Center for Health Statistics, 2001, vol 49, No 2.
  24. National Center for Health Statistics: Estimates of the July 1, 2000, to July 1, 2006, United States resident population from the Vintage 2006 postcensal series by year, county, age, sex, race, and Hispanic origin, prepared under a collaborative arrangement with the US Census Bureau. 2006. (accessed September 8, 2009).
  25. National Center for Health Statistics: Bridged-race intercensal estimates of the July 1, 1990, to July 1, 1999, United States resident population by county, single year of age, sex, race, and Hispanic origin, prepared by the US Census Bureau with support from the National Cancer Institute. 2004. (accessed September 8, 2009).
  26. Klein RJ, Schoenborn CA: Age adjustment using the 2000 projected US population. Healthy People Statistical Notes, No 20. Hyattsville, National Center for Health Statistics, 2001.
  27. Kleinbaum D, Kupper L, Muller K, Nizam A: Applied Regression Analysis and Multivariate Methods. Pacific Grove, Duxbury, 1998.
  28. Dworkin MS, Wan PC, Hanson DL, Jones JL: Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 1999;180:621–625.
  29. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC, Multicenter AIDS Cohort Study Group: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001;56:257–260.
  30. Engsig F, Hansen A, Omland L, Kronborg G, Gerstoft J, Laursen A, Pedersen C, Mogensen C, Nielsen L, Obel N: Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009;199:77–83.
  31. Ammassari A, Cingolani A, Pezzotti P, de Luca DA, Murri R, Giancola ML, Larocca LM, Antinori A: AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000;55:1194–1200.
  32. Antinori A, Ammassari A, Giancola ML, Cingolani A, Grisetti S, Murri R, Alba L, Ciancio B, Soldani F, Larussa D, Ippolito G, de Luca A: Epidemiology and prognosis of AIDS-associated progressive leukoencephalopathy in the HAART era. J Neurovirol 2001;7:323–328.
  33. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999;282:2220–2226.
  34. d’Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J, EuroSIDA Study Group: Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320–328.
  35. Centers for Disease Control and Prevention: HIV/AIDS surveillance report. Atlanta, Centers for Disease Control and Prevention, 1996, vol 8, No 2, p 20.
  36. Centers for Disease Control and Prevention: HIV/AIDS surveillance report. Atlanta, Centers for Disease Control and Prevention, 2006, vol 18, table 7.
  37. Centers for Disease Control and Prevention: HIV/AIDS among persons aged 50 and older: CDC HIV/AIDS facts. 2008. factsheets/pdf/over50.pdf (accessed December 2, 2009).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50